Trial Profile
A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination With Liposomal Doxorubicin (Caelyx) in Patients With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 01 Sep 2022
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Doxorubicin liposomal
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 25 Aug 2022 Status changed from active, no longer recruiting to discontinued.
- 10 Aug 2021 Planned End Date changed from 31 Jul 2021 to 31 Mar 2022.
- 03 Feb 2021 Planned End Date changed from 30 Jun 2020 to 31 Jul 2021.